Endogenous Galectin-1 Modulates Cell Biological Properties of Immortalized Retinal Pigment Epithelial Cells In Vitro.
ARPE-19
cell attachment
cell proliferation
cell viability
compensatory gene expression
epithelial–mesenchymal transition
galectin-1
galectin-1 deficiency
galectin-1 knockout
retinal pigment epithelium cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
10 Aug 2023
10 Aug 2023
Historique:
received:
08
06
2023
revised:
30
07
2023
accepted:
06
08
2023
medline:
28
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
In the eye, an increase in galectin-1 is associated with various chorioretinal diseases, in which retinal pigment epithelium (RPE) cells play a crucial role in disease development and progression. Since little is known about the function of endogenous galectin-1 in these cells, we developed a galectin-1-deficient immortalized RPE cell line (ARPE-19-LGALS1
Identifiants
pubmed: 37628816
pii: ijms241612635
doi: 10.3390/ijms241612635
pmc: PMC10454680
pii:
doi:
Substances chimiques
Galectin 1
0
RNA, Guide, CRISPR-Cas Systems
0
Actins
0
Retinal Pigments
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : OH 214/4-3; PR 1248/2-3
Références
Oncotarget. 2016 Dec 13;7(50):83611-83626
pubmed: 27835885
Expert Rev Neurother. 2020 May;20(5):439-448
pubmed: 32303136
J Biol Chem. 2009 Sep 25;284(39):26860-70
pubmed: 19635795
Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5988-96
pubmed: 19608542
PLoS Genet. 2017 Jul 13;13(7):e1006780
pubmed: 28704371
Nat Commun. 2013;4:1613
pubmed: 23511477
Aging (Albany NY). 2021 Jul 14;13(14):18464-18481
pubmed: 34260413
J Cell Physiol. 2015 Jun;230(6):1298-309
pubmed: 25469885
Biosci Rep. 2020 Jun 26;40(6):
pubmed: 32495835
Semin Cell Dev Biol. 2018 Nov;83:42-50
pubmed: 29501720
Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3575-82
pubmed: 12407170
J Cell Sci. 2018 May 1;131(9):
pubmed: 29717004
Glycobiology. 2021 Sep 9;31(8):891-907
pubmed: 33498084
FASEB J. 2019 Feb;33(2):2498-2513
pubmed: 30277820
Mol Vis. 2009 Oct 23;15:2162-73
pubmed: 19898636
Mol Vis. 2015 Sep 02;21:1036-50
pubmed: 26392742
Invest Ophthalmol Vis Sci. 1993 Aug;34(9):2761-8
pubmed: 7688361
Cell. 1994 Feb 25;76(4):597-8
pubmed: 8124704
PLoS One. 2022 Mar 23;17(3):e0265805
pubmed: 35320287
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):415-26
pubmed: 16384992
Exp Eye Res. 2014 Sep;126:1-4
pubmed: 25152358
Mol Vis. 2017 Mar 05;23:60-89
pubmed: 28356702
Nat Rev Drug Discov. 2023 Apr;22(4):295-316
pubmed: 36759557
Glycobiology. 2006 Nov;16(11):137R-157R
pubmed: 16840800
Acta Ophthalmol. 2020 Feb;98(1):e1-e12
pubmed: 31318490
Molecules. 2022 Jul 26;27(15):
pubmed: 35897964
Mol Cell Proteomics. 2017 Aug;16(8):1528-1546
pubmed: 28576849
FASEB J. 2022 Sep;36(9):e22516
pubmed: 36006656
Metabolites. 2022 Sep 30;12(10):
pubmed: 36295832
Biochem Biophys Res Commun. 2003 Oct 24;310(3):1010-6
pubmed: 14550305
Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1550-6
pubmed: 16565391
Trends Biotechnol. 2019 Apr;37(4):402-415
pubmed: 30413271
Curr Eye Res. 2019 Mar;44(3):341-349
pubmed: 30373411
Sci Rep. 2017 Sep 8;7(1):11006
pubmed: 28887481
PLoS One. 2013 Jul 29;8(7):e70011
pubmed: 23922889
Cell Death Dis. 2018 Mar 16;9(4):416
pubmed: 29549328
Sci Signal. 2014 Sep 23;7(344):re8
pubmed: 25249658